Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2003
11/25/2003US6653133 Antisense modulation of Fas mediated signaling
11/25/2003US6653116 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
11/25/2003US6653098 Transforming cell with an expression vector comprising an isolated polynucleotide; solubilizing the inclusion bodies; refolding and purifying; urea, dithiothreitol and cysteine; angiogenesis inhibitors; anticarcinogenic agents
11/25/2003US6652890 Treating cancer cells that express a membrane protein tNOX, a hormone-insensitive and drug-responsive form of NOX (NADH oxidase) specific to cancer cells
11/25/2003US6652884 Method for the treatment of solid tumors by albumin microparticles incorporating paclitaxel
11/25/2003US6652877 With lipid or liposomal compounds
11/25/2003US6652853 Useful for treating patients with colorectal cancer and gastric carcinomas; particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
11/25/2003CA2258811C Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
11/25/2003CA2194166C Multi-stage cascase boosting vaccine
11/25/2003CA2105014C Imidazolidine derivatives
11/22/2003WO2005032452A2 Alkyl-substituted pcdf as a treatment for prostate cancer
11/22/2003CA2497877A1 Alkyl pcdf as a treatment for prostate cancer
11/21/2003CA2428112A1 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
11/20/2003WO2003096017A1 Methods and compositions for inducing an immune response
11/20/2003WO2003095678A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003WO2003095665A2 Pmea and pmpa cyclic producing synthesis
11/20/2003WO2003095656A1 Recombinant fowlpox virus
11/20/2003WO2003095642A2 Polyepitopes and mini-genes for cancer treatment
11/20/2003WO2003095634A1 Pax-5-deficient pro-b-cells, methods of producing them and the use of such cells in human therapy
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095498A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003WO2003095486A1 Use of a peptide derived from the beta-subunit of hcg in order to generate an anti-tumour ctl-type response
11/20/2003WO2003095484A2 Polypeptides increasing p53 expression
11/20/2003WO2003095470A1 Platinum complexes having antitumor activity
11/20/2003WO2003095462A2 Platinum complexes containing chemically modified bile acids, having antitumor activity
11/20/2003WO2003095461A1 Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
11/20/2003WO2003095460A1 Cascade esters of camptothecins and methods of treating cancer using these compounds
11/20/2003WO2003095459A2 Alkaloid-derived compounds and use thereof in cancer and malaria treatment
11/20/2003WO2003095457A1 Adenosine a3 receptor modulators
11/20/2003WO2003095453A1 Compounds against helicobacter activity
11/20/2003WO2003095452A1 Substituted pyrroline kinase inhibitors
11/20/2003WO2003095448A1 Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
11/20/2003WO2003095447A1 Process for the preparation of a hydrate of an anthranilic acid derivative
11/20/2003WO2003095436A1 Benzoisoselenazole derivatives with anti-inflammation, antivirus and anti-thrombosis activity and their use
11/20/2003WO2003095433A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003WO2003095403A1 Polyunsaturated linear aldehydes and their derivatives with anti-radical and anti-tumoral activity
11/20/2003WO2003094991A1 Medical products comprising a haemocompatible coating, production and use thereof
11/20/2003WO2003094990A1 Compounds and method for coating surfaces in a haemocompatible manner
11/20/2003WO2003094974A1 Complexes for the delivery of biologically-active material to cells
11/20/2003WO2003094963A2 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003WO2003094952A1 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/20/2003WO2003094946A1 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid
11/20/2003WO2003094939A1 Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
11/20/2003WO2003094938A1 Method for reducing pain using oncolytic viruses
11/20/2003WO2003094922A1 Use of cisplatin in combination with folic acid for increasing cisplatin efficacy
11/20/2003WO2003094916A1 Methods of using thiazolidine derivatives to treat cancer or inflammation
11/20/2003WO2003094914A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003WO2003094911A1 Hepatoprotective activity of 10-o-p-hydroxybenzoyiaucubin
11/20/2003WO2003094910A1 Use of 8-prenylflavanones for anti-angiogenesis therapy and for fibrinolytic therapy
11/20/2003WO2003094861A2 Bis-benzimidazoles and related compounds as potassium channel modulators
11/20/2003WO2003094859A2 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003WO2003094850A2 Lipid a and other carbohydrate ligand analogs
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094831A2 Novel diazabicyclic biaryl derivatives
11/20/2003WO2003094829A2 Pathogen vaccines and methods for using the same
11/20/2003WO2003094828A2 Cancer vaccines and methods of using the same
11/20/2003WO2003087062A3 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
11/20/2003WO2003073995A3 Dna vaccine against proliferating endothelial cells and methods of use thereof.
11/20/2003WO2003070192A9 Compositions and methods for surrogate antibody modulation of an immune response and transport
11/20/2003WO2003065971A9 Non-myeloablative tolerogenic treatment with tyrphostins
11/20/2003WO2003061696A3 Systems and methods for photodynamic therapy
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003049772A3 Guanidinium transport reagents and conjugates
11/20/2003WO2003049752A3 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
11/20/2003WO2003044172A3 Composition comprising and method of using angiopoietin-like protein 3 angptl3
11/20/2003WO2003042357A3 Enzymes
11/20/2003WO2003040399A3 Therapeutic methods for nucleic acid delivery vehicles
11/20/2003WO2003039458A3 TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
11/20/2003WO2003038110A3 7118, a human arginine n-methyltransferase family member and uses therefor
11/20/2003WO2003033529A3 Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases
11/20/2003WO2003032984A8 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
11/20/2003WO2003027076A3 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
11/20/2003WO2003024357A3 Microfabricated nanopore device for sustained release of therapeutic agent
11/20/2003WO2003020909A3 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
11/20/2003WO2003020210A3 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
11/20/2003WO2003017946A3 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
11/20/2003WO2003016468A3 Antagonistic anti-htnfsf13b human antibodies
11/20/2003WO2003016344A3 Use of lung carcinoma antigen
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003011217A9 Grifola extracts and methods of use thereof
11/20/2003WO2003009816A3 Facile detection of polycythemia vera
11/20/2003WO2003008444A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/20/2003WO2003007884A3 Method and reagents for identifying gene targets for treating breast cancer
11/20/2003WO2003006509A3 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
11/20/2003WO2003006447A3 Interaction inhibitors of tcf-4 with beta-catenin
11/20/2003WO2003004613A3 Novel pgc-1 isoforms and uses therefor
11/20/2003WO2003000864A3 Nucleic acid-associated proteins
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002102315A3 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
11/20/2003WO2002090530A3 Kinases and phosphatases
11/20/2003WO2002087583B1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002067941A3 Combination comprising a signal transduction inhibitor and an epothilone derivative
11/20/2003WO2002062368A8 Method of inducing a ctl response
11/20/2003WO2002061110A8 Nucleic acid derivatives
11/20/2003WO2002056823A8 Redox therapy for tumors
11/20/2003WO2002055547A3 Sfrp and peptide motifs that interact with sfrp and methods of their use
11/20/2003WO2002044417A9 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
11/20/2003WO2002038744A3 Proteases
1 ... 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 ... 2211